Risk for breakthrough SARS-CoV-2 infection lower with mRNA-1273
Feb 02, 2022
The risk for breakthrough infection and of 60-day hospitalization was significantly lower for mRNA-1273 (Moderna) versus BNT162b2 (Pfizer-BioNTech) vaccination.
Vaccination ups infection-acquired immunity against SARS-CoV-2
Mar 01, 2022
Two doses of the BNT162b2 (Pfizer-BioNTech) vaccine were linked to high short-term protection against infection, which wanes after six months.
Vaccination cuts risk for myocardial infarction, stroke after COVID-19
Jul 29, 2022
The findings show a lower hospitalization risk 31 to 120 days after COVID-19 infection.
Natural immunity protects against SARS-CoV-2 reinfection
Dec 16, 2021
The efficacy of natural infection against reinfection was estimated at 92.3 and 97.6% for beta and alpha variants in cohort in Qatar.
Breakthrough COVID-19 infection risk higher with immune dysfunction
Dec 28, 2021
A breakthrough infection after full vaccination was more likely among older people and women.
Burden of persistent symptoms high after COVID-19 infection
May 24, 2022
No specific causes of symptoms of postacute sequelae of SARS-CoV-2 infection were identified.
CDC: Unvaccinated should not travel this Labor Day weekend
Sep 01, 2021
The agency urges fully vaccinated people to travel with precautions and take infection risk into consideration.
Respiratory virus detections decreased during COVID-19
Jun 22, 2021
Monthly antibiotic prescriptions for respiratory tract infections decreased 79% during pandemic period.
Two doses of mRNA-1273 effective against SARS-CoV-2 variants
Dec 15, 2021
Vaccine effectiveness against infection with delta variant declines with increasing time since vaccination.
OIG audit gives home health industry a passing grade with room for improvement
By
Diane Eastabrook
Sep 29, 2021
Six out of eight home health agencies had infection control policies and procedures in place that met Centers for Medicare & Medicaid Services requirements.